Results 51 to 60 of about 2,092 (196)

Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain [PDF]

, 2016
The research of efficacious non-invasive therapies for the treatment of brain diseases represents a huge challenge, as people affected by disorders of the central nervous system (CNS) will significantly increase.
Belletti, Daniela, Forni, Flavio, Pederzoli, Francesca, Ruozi, Barbara, Tosi, Giovanni, Vandelli, Maria Angela   +5 more
core   +1 more source

Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy

Journal of Stroke and Cerebrovascular Diseases
This article provides perspectives on the use of Cerebrolysin as an adjunct treatment to reperfusion therapy in acute ischemic stroke (AIS). In the evolving landscape of AIS reperfusion therapy, we hypothesize that adjunctive cerebroprotective therapy ...
Marc Ribó, Jacek Staszewski, Steven R. Zeiler, Sławomir Michalak, Ahmed El Bassiouny, Fernando Gongora-Rivera, Zdravka Poljakovic, Dina R Khasanova, Mikhail N Kalinin, Aurauma Chutinet, Roni Eichel, Klaudyna Kojder, Marissa Ong, Marina Roje Bedeković, Chien-Hung Chang, Minwoo Lee, Peter Quitasol, Alexander Tsiskaridse, Natan M Bornstein   +18 more
doaj   +1 more source

The Role of Nutrition in Degenerative Cervical Myelopathy: A Systematic Review. [PDF]

, 2021
INTRODUCTION: Degenerative cervical myelopathy (DCM) is the commonest cause of adult spinal cord impairment worldwide, encompassing chronic compression of the spinal cord, neurological disability and diminished quality of life.
Ahmed, Shahzaib, Akhbari, Melika, Bhatti, Aniqah, Bhatti, Faheem, Davies, Benjamin M, Mowforth, Oliver D, Partha Sarathi, Celine I, Sinha, Amil   +7 more
core   +2 more sources

Clinical outcomes and safety of neuromodulation in hemorrhagic stroke patients with a Glasgow Coma Scale above eight and non-operative lesions: Focusing on neurological recovery in the Thai context

World Neurosurgery: X
Objectives: Hemorrhagic stroke leads to significant brain dysfunction and complex neurological sequelae, even with aggressive surgical interventions aimed at preventing secondary brain injury.
Panu Boontoterm, Siraruj Sakoolnamarka, Karanarak Urasyanandana, Pusit Fuengfoo   +3 more
doaj   +1 more source

Twenty years of therapeutic development in tauopathy mouse models: a scoping review

Alzheimer's &Dementia, Volume 21, Issue 8, August 2025.
Abstract Tauopathies are neurodegenerative diseases characterized by pathological tau protein inclusions and dementia. Tauopathy mouse models with MAPT mutations replicate tau‐related pathologies and are widely used for therapeutic research. This scoping review examines 409 treatment evaluations in MAPT mouse models.
Vanessa F. Langness, Danielle A. Simmons, Tyne L. M. McHugh, Robert R. Butler III, James Zhou, Harry Liu, Tao Yang, Lisa M. Ellerby, Frank M. Longo   +8 more
wiley   +1 more source

A Retrospective Study of Cerebrolysin in Patients With Moderate to Severe Traumatic Brain Injury: Cognitive and Functional Outcomes [PDF]

, 2023
In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a highly severe disability level. A total of 44
González, Javiera, Muñoz, Daniel, Olivares, Sandra, Romero, Violeta, Salinas, Pablo, Soto, Claudio, Sáez, Virginia   +6 more
core   +1 more source

The Pathobiology of Cerebrovascular Lesions in CADASIL Small Vessel Disease

Basic &Clinical Pharmacology &Toxicology, Volume 136, Issue 5, May 2025.
ABSTRACT Cerebral small vessel disease (cSVD) is a significant global health issue, accounting for approximately 25% of ischemic strokes and 20% of all dementia cases. CADASIL, the most common monogenic form of cSVD, is caused by stereotyped mutations in the NOTCH3 receptor that alter the number of cysteine residues in its extracellular domain ...
Anne Joutel
wiley   +1 more source

Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage

BMC Neurology, 2020
Asbtract Background There are limited neuroprotective treatment options for patients with aneurysmal subarachnoid hemorrhage (SAH). Cerebrolysin, a brain-specific proposed pleiotropic neuroprotective agent, has been suggested to improve global functional
Peter Y. M. Woo, Joanna W. K. Ho, Natalie M. W. Ko, Ronald P. T. Li, Leo Jian, Alberto C. H. Chu, Marco C. L. Kwan, Yung Chan, Alain K. S. Wong, Hoi-Tung Wong, Kwong-Yau Chan, John C. K. Kwok   +11 more
doaj   +1 more source

Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability [PDF]

, 2021
Cerebrolysin has been shown to promote neurovascular protection and repair in preclinical models of stroke and neural injury and is demonstrating promise for stroke and neural injury therapeutic application in the clinic.
Chopp, Michael, Fleckenstein, Burkhard, Li, Chao, Lu, Mei, Melcher-Mourgas, Melanie, Teng, Hua, Zhang, Yi, Zhang, Zhenggang   +7 more
core   +1 more source

Neuroprotection for neonatal hypoxic–ischemic encephalopathy: A review of novel therapies evaluated in clinical studies

Developmental Medicine &Child Neurology, Volume 67, Issue 5, Page 591-599, May 2025.
Hypoxic‐ischemic encephalopathy (HIE) is a neurologic condition that is caused by insufficient oxygen and blood flow to a newborn infant’s brain. Although therapeutic hypothermia can reduce the degree of brain injury in some infants with HIE, many infants with HIE will have significant lifelong disabilities despite receiving this treatment.
Natalie H. Chan, Cheryl C. Hawkins, Benjamin V. Rodrigues, Marie‐Coralie Cornet, Fernando F. Gonzalez, Yvonne W. Wu   +5 more
wiley   +1 more source